Selank

Also known as Thr-Lys-Pro-Arg-Pro-Gly-Pro.

Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.

Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.

At-a-glance profile

Classification: Synthetic tuftsin analogue (anxiolytic research)
Approval status: Investigational · Not approved for human use
Research status: Investigational / reference listing.
Molecular formula: Insufficient reliable evidence identified.
Molecular weight: Insufficient reliable evidence identified.
Sequence: Heptapeptide tuftsin analogue: Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Primary biological target: Insufficient reliable evidence identified.
Half-life: Insufficient reliable evidence identified.
Routes investigated: Insufficient reliable evidence identified.
Human evidence level: C — Limited or early human evidence

What is it?

An investigational peptide studied for anxiety-related and immunomodulatory research. Not an Australian approved psychotropic medicine.

Mechanism of action

Proposed GABAergic and enkephalin-related modulation; evidence is preliminary by global drug-development standards.

Not characterised as a first-line anxiolytic in Australian clinical guidelines.

What is it being studied for?

Anxiety models
Immune peptide research

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: C · Limited or early human evidence

Human research

Limited, regionally concentrated clinical literature; not TGA-evaluated.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

Animal anxiolytic models exist.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Safety

Poorly defined in unregulated use; product quality unknown.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Not for human use in Australia outside trials.

Regulatory status

Investigational / locally registered in some regions only.

Not ARTG-registered. Educational listing. Not sold.

Citations

[1] Selank experimental anxiolytic literature
Selank experimental anxiolytic literature

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Cognitive · Compare peptides